BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sunshine Lake Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sunshine Lake Pharma's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04984512-833@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Mitizodone phosphate: Phase 2/3 readout est. (NCT04984512)
DESCRIPTION:Mitizodone phosphate\, phase 2/3\, Major Depressive Disorder.\n
 Study: The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Trea
 tment of Patient With Major Depressive Disorder\nEstimated primary complet
 ion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mitiz
 odone-phosphate#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04984512
URL:https://assetmemo.bio/drug/mitizodone-phosphate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05586074-3016@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Clifutinib Besylate: Phase 3 readout est. (NCT05586074)
DESCRIPTION:Clifutinib Besylate\, phase 3\, Acute Myeloid Leukemia.\nStudy:
  HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML\nEstimated prima
 ry completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/clifutinib-besylate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05586074
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05133882-3016@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Clifutinib Besylate: Phase 1/2 readout est. (NCT05133882)
DESCRIPTION:Clifutinib Besylate\, phase 1/2\, Acute Myeloid Leukemia.\nStud
 y: A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Ch
 emotherapy in the Treatment of Newly Diagnosed AML\nEstimated primary comp
 letion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/clifutinib-besylate#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05133882
URL:https://assetmemo.bio/drug/clifutinib-besylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891377-930@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:HEC53856: Phase 2 readout est. (NCT07891377)
DESCRIPTION:HEC53856\, phase 2.\nStudy: HEC53856 Tablets for Chemotherapy-i
 nduced Anemia in Non-myeloid Malignancies\nEstimated primary completion: F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hec5385
 6#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 891377
URL:https://assetmemo.bio/drug/hec53856#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
